Literature DB >> 12864755

Hormonal factors in migraine: a population-based study of women aged 40 to 74 years.

Peter Mattsson1.   

Abstract

OBJECTIVE: This study investigated some of the relationships between migraine and hormonal factors.
METHODS: A neurologist clinically assessed 728 women aged 40 to 74 years attending a population-based mammography screening program. Headache criteria proposed by the International Headache Society were used. Data on hormonal factors were obtained by interview and questionnaire.
RESULTS: Twenty-one percent of women with migraine without aura and 4% of women with migraine with aura reported that they experienced >/=75% of their attacks within -2 to +3 days of the menstrual cycle. During pregnancy, women experienced less frequent or less intense attacks of migraine without aura and migraine with aura. A small but significant proportion (12%, P =.04) of women with migraine without aura also had premenstrual disorder. Associations between migraine and menarche, pregnancy, pregnancy-related complications, and menopausal complaints were generally weak and insignificant. Migraine with aura was not related to menopause. A crude odds ratio of 0.47 (95% confidence interval [CI] 0.24-0.86) indicated a decrease in risk for migraine without aura in postmenopausal women. However, after adjusting for differences in age and the use of hormonal replacement therapy, this association was not statistically significant. Time since menopause was a significant factor for migraine without aura in postmenopausal women.
CONCLUSION: Although many women with migraine reported a close relationship between their attacks and menses, and relief during pregnancy, the cross-sectional associations between migraine and menopause and menopausal complaints were insignificant.

Entities:  

Mesh:

Year:  2003        PMID: 12864755     DOI: 10.1046/j.1526-4610.2003.03005.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  29 in total

Review 1.  Transdermal hormonal therapy in perimenstrual migraine: why, when and how?

Authors:  Cristina Tassorelli; Rosaria Greco; Marta Allena; Erica Terreno; Rossella E Nappi
Journal:  Curr Pain Headache Rep       Date:  2012-10

Review 2.  Migraine in pregnancy and lactation.

Authors:  Paru S David; Juliana M Kling; Amaal J Starling
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

3.  Self-reported menstrual migraine in the general population.

Authors:  Kjersti Grøtta Vetvik; E Anne MacGregor; Christofer Lundqvist; Michael Bjørn Russell
Journal:  J Headache Pain       Date:  2010-02-26       Impact factor: 7.277

Review 4.  Current Treatment Options: Headache Related to Menopause-Diagnosis and Management.

Authors:  Clinton G Lauritsen; Abigail L Chua; Stephanie J Nahas
Journal:  Curr Treat Options Neurol       Date:  2018-03-06       Impact factor: 3.598

Review 5.  The risks of women with migraine during pregnancy.

Authors:  Gianni Allais; Ilaria Castagnoli Gabellari; Paola Borgogno; Cristina De Lorenzo; Chiara Benedetto
Journal:  Neurol Sci       Date:  2010-06       Impact factor: 3.307

Review 6.  Menstrual migraine.

Authors:  Ana Recober; Lynne O Geweke
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

Review 7.  Genetics of menstrual migraine: the epidemiological evidence.

Authors:  Michael Bjørn Russell
Journal:  Curr Pain Headache Rep       Date:  2010-10

8.  Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium.

Authors:  Vincent T Martin; Jeanne Ballard; Michael P Diamond; Lisa K Mannix; Frederick J Derosier; Shelly E Lener; Alok Krishen; Susan A McDonald
Journal:  J Womens Health (Larchmt)       Date:  2014-02-28       Impact factor: 2.681

Review 9.  Menstrual migraine: a review of prophylactic therapies.

Authors:  Vincent T Martin
Journal:  Curr Pain Headache Rep       Date:  2004-06

10.  Headache and hormone replacement therapy in the postmenopausal woman.

Authors:  E Anne MacGregor
Journal:  Curr Treat Options Neurol       Date:  2009-01       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.